title: [Does PSA of less than 20 ng/ml exclude the diagnosis of metastatic prostate cancer?].
abstract: OBJECTIVE
  To demonstrate the considerable risk of bone metastases from clinically localized prostatic cancer with PSA greater than 20 ng/ml.
  
  
  METHODS
  Patients presenting an indication for radical prostatectomy (younger than 70, with localized prostate cancer, less than 6 out of 9 positive biopsies) and PSA less than 20 ng/ml (Tandem) were selected for this intent-to-treat study.
  
  
  RESULTS
  Seven of the 210 patients corresponding to the selection criteria presented with bone metastases and 4 of them had a PSA less than 10 ng/ml. None had lymph node metastases.
  
  
  CONCLUSIONS
  The risk of bone metastases despite PSA less than 20 ng/ml is therefore not negligible. In our opinion, it is necessary therefore to continue to include bone scan in the staging assessment of clinically localized prostate cancer.
authors.affiliation: Service d'Urologie, Hôpital Henri Mondor, Créteil, France.
authors.forename: D
authors.initials: D
authors.lastname: Amsellem
authors.forename: N
authors.initials: N
authors.lastname: Ogiez
authors.forename: L
authors.initials: L
authors.lastname: Salomon
authors.forename: D
authors.initials: D
authors.lastname: Chopin
authors.forename: C C
authors.initials: CC
authors.lastname: Abbou
authors.forename: M
authors.initials: M
authors.lastname: Colombel
mesh_terms: D000368:Aged; D001706:Biopsy; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery; D011877:Radionuclide Imaging; D013997:Time Factors
chemical_list: D017430:Prostate-Specific Antigen